@article{3122777, title = "Immunogenicity and side-effects of the inactivated hepatitis A vaccine in periodic fever, aphthous stomatitis, pharyngitis, and adenitis patients", author = "Maritsi, D.N. and Syrmou, A. and Vartzelis, G. and Diamantopoulos, S. and Tsolia, M.N.", journal = "Pediatrics International", year = "2019", volume = "61", number = "1", pages = "104-106", publisher = "Blackwell Publishing Inc.", issn = "1328-8067, 1442-200X", doi = "10.1111/ped.13719", keywords = "hepatitis A vaccine; immunoglobulin G; hepatitis A vaccine; immunoglobulin G, Article; child; clinical article; cohort analysis; controlled study; drug efficacy; drug safety; drug tolerability; female; fever; Greece; hepatitis A; human; humoral immunity; injection site induration; malaise; male; observational study; pediatrics; PFAPA syndrome; priority journal; prospective study; seroconversion; vaccination; vaccine immunogenicity; blood; case control study; hereditary periodic fever; immunology; preschool child, Case-Control Studies; Child; Child, Preschool; Female; Hepatitis A Vaccines; Hereditary Autoinflammatory Diseases; Humans; Immunity, Humoral; Immunoglobulin G; Male; Prospective Studies", abstract = "The aim of this study was to compare the immunogenicity and side-effects of hepatitis A virus (HAV) vaccination between periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) patients and healthy controls who have not been previously exposed to HAV. A prospective observational study was carried out of 28 PFAPA patients and 76 controls who received two doses of the vaccine. Immunogenicity was expressed as seroconversion and seroprotection rates; mean HAV-immunoglobulin G concentration was measured at 0, 1, 7 and 18 months. Side-effects were defined as incidence of adverse events and the effect of vaccination on PFAPA symptoms. All participants were seronegative and seroconverted at 1 month. One month after primary vaccination, 92.9% of PFAPA patients and 77.6% of the controls attained seroprotection, while the rates increased to 100% and 96.1%, respectively, 1 month after the second dose. Seroprotection rates remained adequate 1 year after completion of vaccination. In conclusion, two doses of the inactivated HAV vaccine are well-tolerated and effective in children with PFAPA. © 2019 Japan Pediatric Society" }